Researchers design a tool to induce controlled suicide in human cells

A description of this method has been published in the last issue of the specialized Journal Nucleic Acids Research, included in the group Oxford Journals.

"We have developed a strategy to induce controlled mutations in the cell, which allows us to gradually activate several repair systems that are triggered before the cell enters the cell death programme. Using previous methods, the effects on cells are less specific and may lead to parallel responses that hinder analysis of the results," explains the author of the article, Lluís Ribas de Pouplana, ICREA researcher and head of the Gene Translation Laboratory at IRB Barcelona.

Traditional techniques consist of exposing the cells to drug or compounds that affect protein production, thereby creating instability. Renaud Geslain, a researcher in Ribas' group and first author of the article, "had a brilliant idea to reproduce the same effect within the cell, without the help of compounds alien to the cell," recalls Ribas. Geslain manipulated a component of the cellular protein synthesis machinery that causes the production of defective proteins. "In response to the accumulation of misfolded proteins, the cellular alarm systems are switched on and stress responses are activated. Given that this approach affects all the proteins, we obtain all the reactions possible, not only responses that could be exclusive to one or a few affected proteins."

How to interfere with protein production?

Cells are bags full of proteins and all proteins are formed by large chains of amino acids. Cells continually make these molecules through a highly complex system. One of the components involved in protein production, a process in which the Gene Translation Lab is specialized, is transfer RNA (tRNA). The function of tRNA is to transport the protein synthesis machinery and the precise amino acids required for each protein under construction. Geslain designed new tRNAs, very similar to natural ones, but that place erroneous amino acids into the protein sequences under construction. "When these tRNAs are introduced, the cells starts to make and accumulate defective proteins and it reacts in response. Given that the cell still conserves the healthy proteins present before the introduction of our tRNA, we can observe the extent to which the healthy part can correct the problem. We can also see when these defects are no longer correctible and how and when cells enter the suicide programme."

The lab has started to obtain results using this new tool. Analyses indicate that part of the cell response to the accumulation of misfolded proteins is the production of several micro-RNAs, small molecules that regulate gene expression. "We still don't know what they do or what genes they repress but we are discovering very surprising functional connections," notes the IRB Barcelona researcher.

Besides, Ribas continues, "the biological problem that we induce in the cell is directly linked to neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's, which are caused by the aggregations of misfolded proteins that cause neuronal death." The tool developed at IRB Barcelona will allow the identification of new components of the response mechanisms to these mutations. In the future, these components may become targets for intervention in these and other diseases.